



**Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society**

**CAMBRIDGE, MA, September 14, 2017** – [Catabasis Pharmaceuticals, Inc.](http://www.catabasis.com) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will present results from the open-label extension of the MoveDMD trial following 24 and 36 weeks of edasalonexent treatment in boys with Duchenne Muscular Dystrophy (DMD) at the 22<sup>nd</sup> International Congress of the World Muscle Society. The late breaking abstract and results will be available in the late breaking poster session starting at 10:30am CEST on Wednesday, October 4, 2017. The International Congress of the World Muscle Society is being held October 3 – 7, 2017, at the Palais du Grand Large in Saint Malo, France.

**About Edasalonexent**

Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-κB, a protein that is activated in DMD and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. We are currently conducting the MoveDMD trial, a three-part clinical trial investigating the safety and efficacy of edasalonexent in boys enrolled at ages 4 – 7 affected with DMD (any confirmed mutation). The third part of the trial, an open-label extension with edasalonexent, is ongoing. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit [www.catabasis.com](http://www.catabasis.com).

**About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART Linker<sup>SM</sup> platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

###

Investor and Media Contact

Andrea Matthews  
Catabasis Pharmaceuticals, Inc.  
T: (617) 349-1971  
[amatthews@catabasis.com](mailto:amatthews@catabasis.com)